» Articles » PMID: 31928297

Comparison of Microwave Ablation Treatments in Patients with Renal Secondary and Primary Hyperparathyroidism

Abstract

Microwave ablation (MWA) is feasible for severe renal secondary hyperparathyroidism (SHPT) and primary hyperparathyroidism (PHPT) patients ineligible for parathyroidectomy (PTX). Here we compared the clinical manifestations and characteristics of parathyroid glands in these two groups, and summarized the techniques, safety and efficacy of MWA. Baseline clinical characteristics, ablation-related techniques, adverse events/complications, and efficacy were recorded. In SHPT group, malnutrition, cardiovascular/pulmonary complications, and abnormal bone metabolism were severe. SHPT patients had more hyperplastic parathyroid glands. The volume of each gland was smaller, and the time of ablation for a single parathyroid was shorter in the SHPT group, although there were no significant differences compared with patients in the PHPT group. Three patients in both groups had recurrent laryngeal nerve injuries and all recovered, except for one SHPT patient. By the end of follow-up, serum iPTH levels had decreased from 2400.26 ± 844.26 pg/mL to 429.39 ± 407.93 pg/mL ( < .01) in SHPT and from 297.73 ± 295.32 pg/mL to 72.22 ± 36.51 pg/mL in PHPT group ( < .01). Hypocalcemia was more common ( < .001) and serum iPTH levels were prone to rebound in SHPT patients after MWA. MWA can be reserved for those who had high surgical risks because of less invasiveness. Injuries of recurrent laryngeal nerves should be noticed. The health status, perioperative, and intraoperative procedures were more complicated and all parathyroids found by ultrasound should be ablated completely in SHPT patients.

Citing Articles

Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study.

Qiu X, Gao M, Zhang D, Ji F Sci Rep. 2023; 13(1):16949.

PMID: 37805586 PMC: 10560222. DOI: 10.1038/s41598-023-44204-5.


Advances in the treatment of secondary and tertiary hyperparathyroidism.

Zhang L, Zhang B, Liu X, Wang Z, Qi P, Zhang T Front Endocrinol (Lausanne). 2022; 13:1059828.

PMID: 36561571 PMC: 9763452. DOI: 10.3389/fendo.2022.1059828.


Evaluation of efficacy of ultrasound-guided microwave ablation in primary hyperparathyroidism.

Zhang M, Gao Y, Zhang X, Ding Z, Wang X, Jiang W J Clin Ultrasound. 2022; 50(2):227-235.

PMID: 34984687 PMC: 9303728. DOI: 10.1002/jcu.23134.


Estrogen and estrogen receptors in kidney diseases.

Ma H, Chen S, Du Y Ren Fail. 2021; 43(1):619-642.

PMID: 33784950 PMC: 8018493. DOI: 10.1080/0886022X.2021.1901739.

References
1.
Andrioli M, Riganti F, Pacella C, Valcavi R . Long-term effectiveness of ultrasound-guided laser ablation of hyperfunctioning parathyroid adenomas: present and future perspectives. AJR Am J Roentgenol. 2012; 199(5):1164-8. DOI: 10.2214/AJR.11.8442. View

2.
Wilhelm S, Wang T, Ruan D, Lee J, Asa S, Duh Q . The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016; 151(10):959-968. DOI: 10.1001/jamasurg.2016.2310. View

3.
Stephen A, Mannstadt M, Hodin R . Indications for Surgical Management of Hyperparathyroidism: A Review. JAMA Surg. 2017; 152(9):878-882. DOI: 10.1001/jamasurg.2017.1721. View

4.
Klapperich M, Abel E, Ziemlewicz T, Best S, Lubner M, Nakada S . Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology. 2017; 284(1):272-280. PMC: 5495130. DOI: 10.1148/radiol.2016160592. View

5.
Ma Q, Yang Z, Han X, Liu F, Su D, Xing H . Influence of Parathyroidectomy on Bone Calcium Concentration: Evaluation with Spectral CT in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis-A Prospective Feasibility Study. Radiology. 2017; 284(1):143-152. DOI: 10.1148/radiol.2016161797. View